GFAP Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P14136 |
---|---|
Other Accession | NP_002046 |
Clone Names | 2112908 |
Gene ID | 2670 |
---|---|
Other Names | Glial fibrillary acidic protein, GFAP, GFAP |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP2017b was selected from the C-term region of human GFAP . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | GFAP |
---|---|
Function | GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells. |
Cellular Location | Cytoplasm. Note=Associated with intermediate filaments |
Tissue Location | Expressed in cells lacking fibronectin. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
GFAP is one of the major intermediate filament proteins of mature astrocytes. It is used as a marker to distinguish astrocytes from other glial cells during development. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system.
References
Quintanar, J.L., et al., Parasitol. Res. 90(4):261-263 (2003).Shiroma, N., et al., Brain Dev. 25(2):116-121 (2003).Nielsen, A.L., et al., J. Biol. Chem. 277(33):29983-29991 (2002).Namekawa, M., et al., Ann. Neurol. 52(6):779-785 (2002).Lopez-Egido, J., et al., Exp. Cell Res. 278(2):175-183 (2002).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.